Sarah Whitley, MD
Dermatology · Worcester, MANPI 1316383730
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by UCB SA at 52.1% of the total. 2025 is the largest year on record at $2,453, more than ten times the $113 reported in 2021.
Across 13 payments — averaging $239.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$2K
- AbbVie$958
- Journey Medical Corporation$224
- Galderma Laboratories, L.p.$165
- Incyte Corporation$113
- UCB, Inc.$33
Across 29 payments — averaging $4376.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$127K
What the payments were for
- Consulting fees$1,62552%
- Travel & lodging$71023%
- Food & beverage$78225%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 1 | $1,625 |
| AbbVie | 7 | $958 |
| Journey Medical Corporation | 2 | $224 |
| Galderma Laboratories, L.p. | 1 | $165 |
| Incyte Corporation | 1 | $113 |
| UCB, Inc. | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPZELURA$113
How this compares
$3,118 in reported general payments places this provider in the 65th percentile of 552 dermatology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RemicadeInfliximab | 17 | $224,869 |
| Clindamycin Phosphate | 11 | $364 |
| Triamcinolone Acetonide | 12 | $150 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Worcester
- John HarrisWorcester$15M
- Seth KatesWorcester$64K
- Mehdi Rashighi FiroozabadiWorcester$19K
- Ethan LernerCharlestown$1.7M
- Michael KaminerChestnut Hill$1.1M
- Jeffrey SobellChestnut Hill$986K
- Erik DominguesFall River$736K
- Alexandra KimballBoston$680K
- Arash MostaghimiBoston$591K
- David GreensteinBeverly$540K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.